FMTB Stock UPDATES Fairmouont Bancorp (FMTB) 21.9000 10/29/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Fairmouont Bancorp (FMTB) 21.9000 $FMTB

Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 13, 10:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/cmq2ml/pharmapoint) has announced the addition of the "PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022" report to their offering. The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. The base-year market leader in the US is Roche/Novartis' Lucentis, with $497m in sales, as the drug is the first-to-market anti-VEGF inhibitor approved for the treatment of DME. Lucentis will face stiff competition in Regeneron/Bayer's Eylea, which is currently in Phase III trials for DME. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 5.3 Diabetic Nephropathy: Product Profiles - Major Classes and Brands 5.4 Diabetic Retinopathy: Product Profiles - Major Classes and Brands 5.5 Diabetic Neuropathy: Product Profiles - Major Classes and Brands 6 Opportunity and Unmet Need 6.1 Overview 6.2 Unmet Needs 6.3 Unmet Needs Gap Analysis 6.4 Opportunity: Therapy for the Underlying Cause of the Microvascular Complications of Diabetes 6.5 Opportunity: Patient-Tailored Therapy for the Microvascular Complications of Diabetes 6.6 Opportunity: Efficacious Therapy for Diabetic Nephropathy 6.7 Opportunity: Topical Treatment for Diabetic Retinopathy 6.8 Opportunity: Treatment for Diabetic Neuropathy 7 Pipeline Assessment 7.1 Overview 7.2 Promising Drugs in Clinical Development 7.2.1 Eylea (aflibercept) 7.2.2 Optina (danazol) 7.2.3 Atrasentan Hydrochloride 7.2.4 Ranirestat 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/cm...harmapoint
NVS: 91.87 (-0.48)

10-Q: FAIRMOUNT BANCORP, INC.
Edgar Online - Thu Feb 13, 8:41AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
TINY: 2.86 (-0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Health Net Invests $3 Million in Stockton Housing

Updated Category News Views 145

Putting a Roof Over Stockton's Head The talk of the town in Stockton is Health Net stepping up with a $3 million investment. This isn't just dropping loose change in a jar; it's about tackling a mammoth issue—making affordable housing more than just a pipe dream for 75 families. Community-driven, they say. What a cozy way to paint a picture of bridging that brutal gap...

Continue Reading
Partner Joins Yardi ICN, Boosting Data Quality for Clients

Updated Category News Views 91

Strategic Alliances in Real Estate Data When Partner Engineering and Science, Inc. says they're hooking up with the Yardi Independent Consultant Network (ICN), that's not just some boardroom handshake. It's a play that could shake up data services in the real estate game. Look, there's plenty of chatter about digitizing property management, but without killer data, those...

Continue Reading
Dyania, NVIDIA Team Up: AI Transforming Patient Care

Updated Category News Views 61

Revving up efficiency in healthcare usually sounds like pie-in-the-sky talk, but every now and again, an innovation comes along that really stirs the pot. Enter Dyania Health's Synapsis AI, a clinical reasoning AI, teaming with NVIDIA's robust computing infrastructure. They're setting out to make sense of massive amounts of patient data, securely tucked behind a...

Continue Reading
D-Wave's 9.5% Drop: Fraud Lawsuit Raises Investor Ire

Updated Category News Views 101

Shockwaves from D-Wave's Earnings Call August wasn't exactly a banner month for D-Wave Quantum, Inc. as their stock went down like a lead balloon following a lackluster earnings report. If you've ever had any skin in the game, you'd know a 9.5% drop isn't just peanuts—it's the equivalent of watching your prized racehorse stumble at the first hurdle. The financials spoke...

Continue Reading
Euroandinos Paita Closes Consent for 2037 Notes

Updated Category News Views 70

Port Strategy and Financial Implications Terminales Portuarios Euroandinos Paita S.A., nestled in the Peruvian transport sector, has been tight-rope walking through its debt landscape. Announcing a successful consent solicitation on November 13, 2026, they've taken a significant step towards reconfiguring their long-term financing game. This puppet show of paperwork...

Continue Reading
PenFed Fuels Aggie Spirit with Blackout Game Activation

Updated Category News Views 156

A Different Kind of Game Day Experience Ah, there's nothing quite like the vibrancy of a Texas A&M game day, especially when it's a blackout event. On November 14, fans aren't just getting the good old college football thrills; they're diving headfirst into an extravaganza, courtesy of PenFed Credit Union. You might know them as the go-to credit union for military folks,...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 46

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Fly-E Faces Revenue Drop Amid Retail Restructuring

Updated Category News Views 215

Downturn Despite Strategic Restructuring Today, we're diving into Fly-E Group, Inc. (NASDAQ:FLYE) and the latest shakeup in their financials—spoiler alert, it's riding a downward slope. Quarter two of fiscal 2027 didn't exactly shine a light on profitability. Net revenues slid, dropping to $2.6 million this quarter, down from $3.9 million the previous year. Tack that up...

Continue Reading
LA Fitness ELEVATE Opens at RITHM: A New Era Dawns

Updated Category News Views 66

Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...

Continue Reading
FiEE Rockets to Profitability with 382% Revenue Surge

Updated Category News Views 170

Big Moves in the Tech Jungle: FiEE's Comeback Let's chew the fat on FiEE, Inc., a company that's left its hardware-heavy past in the dust and grabbed the bull by the horns with fresh, AI-driven brand tech solutions. We're talking a whopping 382.1% revenue increase. Now, that's not chump change. From barely scraping $2 million last year to raking in $9.6 million just for...

Continue Reading

Top 5 Most Recently Viewed Articles

Cresilon Expands Reach with New VETIGEL Deal for Veterinarians

Updated Category News Views 267

Cresilon Partners with McCarthy Vet to Distribute VETIGEL Cresilon Inc., an innovative biotechnology firm known for its advanced hemostatic products, has announced a transformative agreement with McCarthy Vet. This collaboration marks a significant step forward as it allows for the distribution of VETIGEL, a groundbreaking hemostatic gel, directly to veterinary surgeons....

Continue Reading
Absci's Upcoming Financial Report and Business Highlights

Updated Category News Views 192

Absci Corporation's Upcoming Financial Reports Absci Corporation (Nasdaq: ABSI), recognized as a pioneer in data-driven generative AI for drug discovery, is gearing up to release important business updates along with financial results for the first quarter of 2025. This report is scheduled to be unveiled subsequent to market close. Key Highlights of the Upcoming Report...

Continue Reading
Upcoming Q2 2025 Results Announcement by Borregaard ASA

Updated Category News Views 186

Borregaard ASA's Second Quarter Results Announcement Borregaard ASA, a renowned name in biochemistry, is set to present its Q2 2025 results. This event will take place on Wednesday, coinciding with July 16, 2025, at 07:00 CEST. As anticipated, a comprehensive stock exchange announcement will follow shortly thereafter. What to Expect from the Presentation The presentation...

Continue Reading
JP Conte's Lupine Crest Pours $14M into Orizon Again

Updated Category News Views 29

JP Conte's Bet on Brazilian Waste-to-Energy Giant Here's the scoop, folks. Lupine Crest Capital, helmed by none other than JP Conte, just doubled down on their investment in Brazil. This isn't some negligible penny-ante increase, but a hefty infusion of R$70 million—think roughly $14 million in USD—into Orizon Valorização de Resíduos S.A., the notable...

Continue Reading
Hedge Funds Shift Strategies Amid Volatile U.S. Equity Markets

Updated Category News Views 121

Hedge funds adjusted their playbooks back then in 2023, net selling equities amid a flurry of options expiry and index rebalancing. The desks were abuzz as they noted slight selling pressure from these funds, yet after the dust settled on that chaotic week, buying picked up noticeably—especially Thursday when it seemed traders found some footing again. Macro Products...

Continue Reading